On April 25, the groundbreaking ceremony for Ypsomed's new production facility took place in the Changzhou National Hi-tech District. In order to be able to efficiently serve the rapidly growing Chinese market for injection systems, Ypsomed is investing over CHF 35 million in the new manufacturing plant in the first phase. Production is expected to commence in the second half of 2024.

The groundbreaking ceremony heralded the start of construction of the new production facility in the Changzhou Industrial Park. The Changzhou National Hi-tech District (CND) industrial park covers 439 km² and is home to more than 10,000 companies, around 1,500 of which are from abroad, and is geared towards the high-tech industry. Construction of the new Ypsomed plant will take about one year. The plant is expected to start operations in the second half of 2024. The Changzhou site will be home to production, logistics warehouse, quality control and technical maintenance, and will manufacture injection systems for the Chinese market. The plant will be equipped with the same state-of-the-art plastic injection moulding machines, printing equipment and automated assembly machines as the plants in Switzerland and Germany.

In the future, pharmaceutical companies will increasingly use disposable products in China, such as the UnoPen or the YpsoMate. Business with disposables is more volume-intensive, which is why the proximity of production to the place of delivery is sought. The city of Changzhou, located in the Yangtze River Delta and to the west of the metropolis of Shanghai, is an up-and-coming trade and industry location favored by many medical companies.

扫一扫在手机打开当前页